Abstract
Development of cytarabine and daunorubicin has made a cure for acute myeloid leukemia (AML) possible. Current first line chemotherapy is a combination of idarubicin plus cytarabine. Acute promyelocytic leukemia has the highest cure rate among AML due to the introduction of ATRA. Current first line chemotherapy for advanced Hodgkin's lymphoma is ABVD, based upon results of a prospective randomized study comparing MOPP, ABVD and MOPP/ABVD. CHOP has been frequently selected as first line chemotherapy for advanced non-Hodgkin's lymphoma, based upon results obtained in a phase III study that compared CHOP versus second and third generation combinations.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Dacarbazine / administration & dosage
-
Daunorubicin / administration & dosage
-
Doxorubicin / administration & dosage
-
Hematologic Neoplasms / drug therapy*
-
Hodgkin Disease / drug therapy
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy
-
Lymphoma, Non-Hodgkin / drug therapy
-
Mechlorethamine / administration & dosage
-
Prednisone / administration & dosage
-
Procarbazine / administration & dosage
-
Vinblastine / administration & dosage
-
Vincristine / administration & dosage
Substances
-
Cytarabine
-
Bleomycin
-
Procarbazine
-
Mechlorethamine
-
Vincristine
-
Vinblastine
-
Dacarbazine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone
-
Daunorubicin
Supplementary concepts
-
ABVD protocol
-
CHOP protocol
-
MOPP protocol